EPCAM and renal cell carcinoma: Notably, a study by Rosato et al. [2] found that anti-CMV T cells infiltrate RCC tumors and can be activated by viral peptides, suggesting that EpCAM-ReTARGTPRIFNαR149A could be particularly effective for RCC treatment.